Lead Sponsor

Almirall, S.A.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

•Participant with diagnosis of moderate or severe chronic plaque PSO documented in the medical chart.
•Participant who needs systemic biologic therapy and qualifies for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-Il-23p19 selected therapy before including the patient in the study.
•Participant aged greater than or equal to (\>=) 18 years at Inclusion.
•Written informed consent.

•Participant unable or unwilling to comply with the requirements of the study.
•Participant who should not participate in the study for any reason at the discretion of the treating physician.
•Participants participating in a simultaneous clinical trial.
•Any contraindication against the use of Tildrakizumab according to the SmPC.
•Exposure to \>= 3 biologics prior to inclusion.
•Participant dependent on the investigator, e.g. as employee

Related studies

NCT07474792 · Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

NCT07116967 · Plaque Psoriasis

NCT07250802 · Plaque Psoriasis

NCT07449702 · Plaque Psoriasis

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting